ArticleFrontiers in microbiology2014
Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains.
Article in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 61 citations in OpenAlex.
- Early and matureBiofilm · 2026Article
- Successful Management ofArthroplasty today · 2026Article
- Genomic insights into the resistome, mobilome and functional adaptation ofMicrobial genomics · 2026Article
- Novel Insight into Dugong Mortality: First Report of SystemicAnimals : an open access journal from MDPI · 2025Article
- Combined effects of ciprofloxacin and microplastics on alpine spring water microbiota: evidence from glacier-fed microcosm experiments.Frontiers in microbiology · 2025Article
- Emergence of Achromobacter xylosoxidans Bacteremia in a Tertiary Care Center: A Case Report and Literature Review.Cureus · 2024Article
- Polymyxin Resistance and Heteroresistance Are Common in Clinical Isolates ofMicrobiology spectrum · 2023Article
- Successful Treatment of Aortic Endocarditis byAntibiotics (Basel, Switzerland) · 2022Review
- Article
- Nasopharyngeal microbiota in hospitalized children with Bordetella pertussis and Rhinovirus infection.Scientific reports · 2021Article
- Adaptive Interactions ofPathogens (Basel, Switzerland) · 2021Article
- Role of RND Efflux Pumps in Drug Resistance of Cystic Fibrosis Pathogens.Antibiotics (Basel, Switzerland) · 2021Review
- Article
- Review
- Achromobacter xylosoxidans Cellular Pathology Is Correlated with Activation of a Type III Secretion System.Infection and immunity · 2020Article
- High Occurrence of Bacterial Competition Among Clinically Documented Opportunistic Pathogens IncludingFrontiers in microbiology · 2020Article
- Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.Applied and environmental microbiology · 2018Article
- Bacterial infections in patients with primary ciliary dyskinesia: Comparison with cystic fibrosis.Chronic respiratory disease · 2017Review
- Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.Journal of clinical microbiology · 2017Article
- A Pan-Genomic Approach to Understand the Basis of Host Adaptation in Achromobacter.Genome biology and evolution · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) patients have chronic airway infection and frequent exposure to antibiotics, which often leads to the emergence of resistant organisms. Achromobacter xylosoxidans is a new emergent pathogen in CF spectrum. From 2005 to 2010 we had an outbreak in A. xylosoxidans prevalence in our CF center, thus, the present study was aimed at deeply investigating virulence traits of A. xylosoxidans strains isolated from infected CF patients. To this purpose, we assessed A. xylosoxidans genome variability by randomly amplified polymorphic DNA (RAPD), biofilm production, antibiotic resistances, and motility. All A. xylosoxidans strains resulted to be biofilm producers, and were resistant to antibiotics usually employed in CF treatment. Hodge Test showed the ability to produce carbapenemase in some strains. Strains who were resistant to β-lactamics antibiotics, showed the specific band related to metal β-lactamase (blaIMP-1), and some of them showed to possess the integron1. Around 81% of A. xylosoxidans strains were motile. Multivariate analysis showed that RAPD profiles were able to predict Forced Expiratory Volume (FEV1%) and biofilm classes. A significant prevalence of strong biofilm producers strains was found in CF patients with severely impaired lung functions (FEV1% class 1). The outbreak we had in our center (prevalence from 8.9 to 16%) could be explained by an enhanced adaptation of A. xylosoxidans in the nosocomial environment, despite of aggressive antibiotic regimens that CF patients usually undergo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.